Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: Analysis of the phase 2, open-label, single-arm A2101 study

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 12, 2013, Pages 1985-1993

  Hochhaus, Andreas ^a   Le Coutre, Philipp D ^b   Kantarjian, Hagop M ^c   Baccarani, Michele ^d   Erben, Philipp ^e   Reiter, Andreas ^e   McCulloch, Tracey ^f   Fan, Xiaolin ^f   Novick, Steven ^f   Giles, Francis J ^g  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic eosinophilic leukemia; Hypereosinophilic syndrome; Nilotinib

Indexed keywords

NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHMA; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOCARDITIS; ENDOCARDITIS FIBROPLASTICA; EOSINOPHILIC LEUKEMIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LYMPHOCYTOPENIA; MALE; MYALGIA; MYOPATHY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAPULE; PDGFRALPHA GENE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SODIUM BLOOD LEVEL; SURVIVAL TIME; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84888409115     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1529-7     Document Type: Article

References (49)

1. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha- positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173-1179
2. Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL et al (2008) Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 36(10):1244-1253
3. Buchdunger E, Matter A, Druker BJ (2001) Bcr-abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551(1):M11-M18
4. Butterfield JH (2009) Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 33(8):1127-1129
5. Butterfield JH, Weiler CR (2012) Treatment of hypereosinophilic syndromes - the first 100 years. Semin Hematol 49(2):182-191
6. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al (2003a) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201-1214
7. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al (2003b) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3(5):459-469
8. Cools J, Maertens C, Marynen P (2005) Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Updat 8(3):119-129
9. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E et al (2011) Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600-5606
10. Crane MM, Chang CM, Kobayashi MG, Weller PF (2010) Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126(1):179-181
11. Cross NC, Reiter A (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119(4):199-206
12. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M et al (2011) Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117(10):2935-2943
13. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26(5):959-962
14. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1):107-112
15. Gotlib J (2012) World health organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(9):903-914
16. Gotlib J, Cools J (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22(11):1999-2010
17. Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103(8):2879-2891
18. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 116(21): abstract 316
19. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al (2012) KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: Results of a planned interim analysis of the global CPKC412D2201 trial. Blood 120(Suppl): abstract 799
20. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A et al (2010) Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript-results of Polish multicentre study. Hematol Oncol 28(2):93-97
21. Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemien S (2012) Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 87(6):643-645
22. Ikezoe T, Togitani K, Tasaka T, Nishioka C, Yokoyama A (2010) Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 34(8):e200-e201
23. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354(24):2542-2551
24. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540-3546
25. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103(8):2939-2941
26. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R et al (2012) Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26(6):1189-1194
27. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W et al (2006) Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108(4):1374-1376
28. Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P (2012) Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 26(7):1693-1695
29. Loules G, Kalala F, Giannakoulas N, Papadakis E, Matsouka P, Speletas M (2009) FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC Blood Disord 9:1
30. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M et al (2010) Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18(19):6977-6986
31. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143(5):707-715
32. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al (2012) Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26(1):162-164
33. National Cancer Institute (2006) Common terminology criteria for adverse events (CTCAE), version 3.0
34. Novartis Pharmaceuticals Corporation (January 2012) Gleevec [package insert]
35. Novartis Pharmaceuticals Corporation (May 2012) Tasigna [package insert]
36. Pardanani A, Tefferi A (2004) Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 28(Suppl 1):S47-S52
37. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E et al (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19(5):792-798
38. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215-1228
39. Roufosse F (2009) Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 94(9):1188-1193
40. Roufosse FE, Goldman M, Cogan E (2007) Hypereosinophilic syndromes. Orphanet J Rare Dis 2:37
41. Soverini S, Iacobucci I, Baccarani M, Martinelli G (2007) Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 92(4):437-439
42. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al (2005) The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 106(9):3206-3213
43. Tabouret E, Charbonnier A, Mozziconacci MJ, Ivanov V (2011) Low-dose nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 35(1):136
44. Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH et al (2012) ICON: eosinophil disorders. World Allergy Organ J 5(12):174-181
45. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D et al (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18(4):734-742
46. Verstovsek S (2007) New hematological indications for imatinib. Eur Oncol Dis 1(2):26-28
47. Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P et al (2006) Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 30(12):1499-1505
48. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A et al (2009) Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368-373
49. Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, Valent P et al (2012) Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One 7(2):e30567